Sales Forecast Of Oncology Small Molecule Drugs Market Indicates Positive Outlook Through 2031 : Fact.MR

According to a recent study by Fact.MR, sales of oncology small molecule drugs are envisaged to surpass US$ ~66 Bn in 2019, up from revenues worth US$ ~63 Bn attained in 2018. Gains are prominently underpinned by spectacular rise in cancer prevalence, rapid proliferation of oncology centers, and improving availability of oral small molecule drugs for cancer treatment.

The report suggests that a number of oncology small molecule drugs are getting approvals, which are potentially effective in treating unresectable cancers, which clearly points to a positive growth outlook for the oncology small molecule drugs market.

For detailed insights on enhancing your product footprint, request for a sample here-  https://www.factmr.com/connectus/sample?flag=S&rep_id=3747

Key Segments Covered

  • Route of Administration
    • Oral Oncology Small Molecule Drugs
    • Injectable Oncology Small Molecule Drugs
  • Drug Class
    • Small Molecule Chemotherapy Drugs
      • Alkylating Drugs
      • Antimetabolites
      • Other Drugs
    • Small Molecule Immunomodulating Drugs
    • Small Molecule Targeted Therapy Drugs
      • Proteasome Inhibitors
      • Tyrosine Kinase Inhibitors
      • mTOR Inhibitors
      • Hormonal Therapy
  • Distribution Channel
    • Oncology Small Molecule Drugs Distribution via Hospital Pharmacies
    • Oncology Small Molecule Drugs Distribution via Retail Pharmacies
    • Oncology Small Molecule Drugs Distribution via Specialty clinics
    • Oncology Small Molecule Drugs Distribution via Online Pharmacies
  • Indication
    • Oncology Small Molecule Drugs  for Non-small Cell Lung Cancer
    • Oncology Small Molecule Drugs  for Renal Cell Carcinoma
    • Oncology Small Molecule Drugs  for Breast Cancer
    • Oncology Small Molecule Drugs  for Prostate Cancer
    • Oncology Small Molecule Drugs  for Multiple Myeloma
    • Oncology Small Molecule Drugs  for Melanoma
    • Oncology Small Molecule Drugs  for Lymphoma
    • Oncology Small Molecule Drugs  for Leukaemia
    • Oncology Small Molecule Drugs  for Other Indications

Request Customization – https://www.factmr.com/connectus/sample?flag=RC&rep_id=3747

50% of Sales Remain Concentrated in North America

According to the Fact.MR study, sales of oncology small molecule drugs will remain concentrated in North America, primarily driven by the high prevalence of cancers and advanced treatment infrastructure in the region. Increasing funds from governments as well as private organizations for the development of advanced and improved cancer treatments, will remain the key growth influencers associated with the growth of oncology small molecule drugs market in North America.

In 2018, North America accounted for half the sales of oncology small molecule drugs, and will continue to remain the most lucrative market for stakeholders. Stringent approval regulations, especially in developing countries, such as Japan, will continue to limit the penetration of oncology small molecule drugs in these regions to an extent. Furthermore, Japan, peculiarly having one of the most difficult approval processes for new drug molecules, holds an impressive opportunistic potential for market leaders that are striving for quicker drug approvals by improving R&D processes and expansion strategies, targeting developing countries.

The study opines that advanced and orally viable cancer drugs are adding value to the attractive market potential of oncology small molecule drugs, among an ever-growing pool of patients. Broader factors concerning cancer treatment, especially the unavailability of proper drugs in several regions and laser-sharp focus on increasing drug absorption in cells by leveraging small molecule drugs, are likely to shape revenue generation in the oncology small molecule drugs market.

The demand for oral oncology small molecule drugs market will continue to accelerate at a steady pace, with global adoption through this route of administration estimated to exceed US$ ~56 Bn in 2019. With higher convenience and effectiveness comparable to injectable oncology small molecule drugs, growing demand for oral variants is pacing up gains in the market.

Full Access of this Exclusive Report is Available at-  https://www.factmr.com/checkout/3747

Competitive Landscape

Prominent players are embracing innovative approaches such as ground-breaking marketing tactics, technological advancements, mergers, and acquisitions.

  • In June 2021, Novartis AG has received breakthrough therapy designation from the U.S. Food and Drug Administration for an experimental treatment for advanced castration-resistant prostate cancer-Novartis’ Lu-PSMA-617 – a tumour-targeting radiation therapy
  • In December 2019, Sanofi and Synthorx, Inc., a clinical-stage biotechnology company focused on prolonging and improving the lives of people suffering from cancer and autoimmune disorders, entered into a definitive agreement of approximately $2.5 Bn (on a fully diluted basis).

For More Insight- https://www.factmr.com/article/124/latest-trends-in-the-healthcare-industry-how-has-it-transformed-businesses

About Us:

Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analysed. Our sales offices in United States and Dublin, Ireland. Headquarter based in Dubai, UAE. Reach out to us with your goals, and we’ll be an able research partner.

Contact:

US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583

Corporate Headquarter:
Unit No: AU-01-H Gold Tower (AU),
Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers,
Dubai, United Arab Emirates
Email: sales@factmr.com
Visit Our Website: https://www.factmr.com

About the Author

Leave a Reply

Your email address will not be published.

You may also like these